The FDA has accepted for priority review a new supplemental biologics license application for Winrevair to treat adults with ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

Merck MRK announced a definitive agreement to acquire Verona Pharma VRNA for approximately $10 billion. The deal will add ...

Merck said it plans to advanced MK-0616 into phase 3 trials before the end of this year, looking at both its ability to reduce LDL-cholesterol, as well as cardiovascular outcomes.